Biotech Values

[DewDiligence]

CTIC’s Xyotax trials were a notable example, and there are many others.

This is an excerpt from #msg-14778637:

“…one of the physicians managing a trial of Xyotax was asked to participate in a conference call for investors, most of whom managed hedge funds. The call was supposed to be about two other cancer drugs, but the analyst threw in a question about Xyotax. The physician answered by expressing concern that some of the clinical trials were being done in Eastern Europe. ‘Boom! Our stock went down,’ Bianco recalls.”